- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment closed, Enrollment change: MOMs-CMA: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (clinicaltrials.gov) - Oct 13, 2023
P3, N=97, Active, not recruiting,
Recruiting --> Active, not recruiting | N=200 --> 97
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment closed, Enrollment change: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - May 3, 2023
P3, N=140, Active, not recruiting,
No abstract available Recruiting --> Active, not recruiting | N=200 --> 140
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (clinicaltrials.gov) - Dec 7, 2022
P2, N=2630, Recruiting,
Recruiting --> Active, not recruiting | N=200 --> 140 Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jul 2026
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Nov 14, 2022
P3, N=200, Recruiting,
Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jul 2026 Trial completion date: Sep 2026 --> Dec 2024 | Trial primary completion date: Sep 2025 --> Dec 2024
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-CMA: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (clinicaltrials.gov) - Nov 14, 2022
P3, N=200, Recruiting,
Trial completion date: Sep 2026 --> Dec 2024 | Trial primary completion date: Sep 2025 --> Dec 2024 Trial completion date: Sep 2026 --> Dec 2024 | Trial primary completion date: Sep 2025 --> Dec 2024
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-INO: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (clinicaltrials.gov) - Nov 14, 2022
P3, N=200, Recruiting,
Trial completion date: Sep 2026 --> Dec 2024 | Trial primary completion date: Sep 2025 --> Dec 2024 Trial completion date: Sep 2026 --> Dec 2024 | Trial primary completion date: Sep 2026 --> Dec 2024
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (clinicaltrials.gov) - Dec 2, 2021
P2, N=2630, Recruiting,
Trial completion date: Sep 2026 --> Dec 2024 | Trial primary completion date: Sep 2026 --> Dec 2024 Trial completion date: Feb 2026 --> Jun 2026
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Nov 4, 2021
P3, N=200, Recruiting,
Trial completion date: Feb 2026 --> Jun 2026 Trial completion date: Dec 2026 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2025
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-CMA: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (clinicaltrials.gov) - Nov 4, 2021
P3, N=200, Recruiting,
Trial completion date: Dec 2026 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2025 Trial completion date: Dec 2026 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2025
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-INO: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (clinicaltrials.gov) - Nov 4, 2021
P3, N=200, Recruiting,
Trial completion date: Dec 2026 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2025 Trial completion date: Dec 2027 --> Sep 2026 | Trial primary completion date: Dec 2026 --> Sep 2026
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment change: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Jul 16, 2021
P3, N=200, Recruiting,
Not yet recruiting --> Recruiting | N=300 --> 200 N=300 --> 200
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Phase classification, Enrollment change: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (clinicaltrials.gov) - Mar 15, 2021
P2, N=2630, Not yet recruiting,
Not yet recruiting --> Recruiting Phase classification: P4 --> P2 | N=1630 --> 2630
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial initiation date, Trial primary completion date: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (clinicaltrials.gov) - Feb 10, 2021
P4, N=1630, Not yet recruiting,
Phase classification: P4 --> P2 | N=1630 --> 2630 Trial completion date: Jul 2025 --> Dec 2025 | Initiation date: Oct 2020 --> Apr 2021 | Trial primary completion date: Jul 2025 --> Dec 2025
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Dec 19, 2020
P3, N=300, Recruiting,
Trial completion date: Jul 2025 --> Dec 2025 | Initiation date: Oct 2020 --> Apr 2021 | Trial primary completion date: Jul 2025 --> Dec 2025 Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-CMA: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (clinicaltrials.gov) - Dec 19, 2020
P3, N=300, Recruiting,
Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025 Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-INO: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (clinicaltrials.gov) - Dec 19, 2020
P3, N=300, Not yet recruiting,
Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025 Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment open: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Jul 8, 2020
P3, N=300, Recruiting,
Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026 Not yet recruiting --> Recruiting
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Jun 5, 2020
P3, N=300, Not yet recruiting,
Not yet recruiting --> Recruiting Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2023
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-CMA: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (clinicaltrials.gov) - Jun 5, 2020
P3, N=300, Not yet recruiting,
Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2023 Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2023
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial primary completion date: MOMs-INO: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (clinicaltrials.gov) - Jun 5, 2020
P3, N=300, Not yet recruiting,
Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2023 Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion, Enrollment change: Phase II Pharmacokinetics Study of CAM2038 (clinicaltrials.gov) - Apr 30, 2020
P2, N=66, Completed,
Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024 Active, not recruiting --> Completed | N=50 --> 66
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion, Enrollment change: Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov) - Feb 7, 2020
P3, N=676, Completed,
Active, not recruiting --> Completed | N=50 --> 66 Active, not recruiting --> Completed | N=340 --> 676
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial initiation date, Trial primary completion date: MOMs-CMA: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (clinicaltrials.gov) - Feb 6, 2020
P3, N=300, Not yet recruiting,
Active, not recruiting --> Completed | N=340 --> 676 Trial completion date: Jan 2024 --> Aug 2024 | Initiation date: Nov 2019 --> Mar 2020 | Trial primary completion date: Jan 2023 --> Aug 2023
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial initiation date, Trial primary completion date: MOMs-INO: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (clinicaltrials.gov) - Feb 6, 2020
P3, N=300, Not yet recruiting,
Trial completion date: Jan 2024 --> Aug 2024 | Initiation date: Nov 2019 --> Mar 2020 | Trial primary completion date: Jan 2023 --> Aug 2023 Trial completion date: Jan 2024 --> Aug 2024 | Initiation date: Oct 2020 --> May 2021 | Trial primary completion date: Jan 2024 --> Aug 2024
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion date, Trial initiation date, Trial primary completion date: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Feb 6, 2020
P3, N=300, Not yet recruiting,
Trial completion date: Jan 2024 --> Aug 2024 | Initiation date: Oct 2020 --> May 2021 | Trial primary completion date: Jan 2024 --> Aug 2024 Trial completion date: Jan 2024 --> Aug 2024 | Initiation date: Nov 2019 --> Mar 2020 | Trial primary completion date: Jan 2023 --> Aug 2023
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial initiation date: MOMs: Medication Treatment for Opioid Use Disorder in Expectant Mothers (clinicaltrials.gov) - Sep 24, 2019
P3, N=300, Not yet recruiting,
Trial completion date: Jan 2024 --> Aug 2024 | Initiation date: Nov 2019 --> Mar 2020 | Trial primary completion date: Jan 2023 --> Aug 2023 Initiation date: Aug 2019 --> Nov 2019
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment closed, Trial completion date, Trial primary completion date: Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov) - Jul 18, 2018
P3, N=340, Active, not recruiting,
Phase classification: P=N/A --> P3 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Jan 2019 | Trial primary completion date: Dec 2017 --> May 2018
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion: Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=228, Completed,
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Jan 2019 | Trial primary completion date: Dec 2017 --> May 2018 Active, not recruiting --> Completed
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial completion: Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence (clinicaltrials.gov) - Nov 21, 2016
P3, N=429, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment closed: Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=228, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Trial initiation date, Trial primary completion date: Phase II Pharmacokinetics Study of CAM2038 (clinicaltrials.gov) - Oct 11, 2016
P2, N=50, Active, not recruiting,
Recruiting --> Active, not recruiting Initiation date: Feb 2016 --> Feb 2015 | Trial primary completion date: Sep 2016 --> Mar 2017
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment closed: Phase II Pharmacokinetics Study of CAM2038 (clinicaltrials.gov) - Jul 20, 2016
P2, N=50, Active, not recruiting,
Initiation date: Feb 2016 --> Feb 2015 | Trial primary completion date: Sep 2016 --> Mar 2017 Recruiting --> Active, not recruiting
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
Enrollment closed, Enrollment change: Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence (clinicaltrials.gov) - Apr 12, 2016
P3, N=433, Active, not recruiting,
N=160 --> 228 Recruiting --> Active, not recruiting | N=252 --> 433
- |||||||||| Brixadi once-weekly depot (buprenorphine once-weekly depot) / Braeburn, Camurus, Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
New P2 trial: Phase II Pharmacokinetics Study of CAM2038 (clinicaltrials.gov) - Mar 16, 2016
P2, N=50, Recruiting,
|
